Sex Differences in Coronary Microvascular Function in Individuals With Type 2 Diabetes

Andrea V Haas, Bernard A Rosner, Raymond Y Kwong, Ajay D Rao, Rajesh Garg, Marcelo F Di Carli, Gail K Adler, Andrea V Haas, Bernard A Rosner, Raymond Y Kwong, Ajay D Rao, Rajesh Garg, Marcelo F Di Carli, Gail K Adler

Abstract

Cardiovascular (CV) disease fatality rates are higher for women compared with men with diabetes despite lower rates of obstructive coronary artery disease (CAD). Impaired coronary flow reserve (CFR), the ratio of adenosine-stimulated to rest myocardial blood flow (MBF), is an indicator of coronary microvascular dysfunction and predicts major adverse CV events. We performed a post hoc analysis to determine whether there was a sex disparity in coronary microvascular dysfunction among 46 men and 27 women with well-controlled type 2 diabetes and without clinical evidence of obstructive CAD. We found that women had a higher rest MBF, lower CFR, and worse diastolic function compared with men. In addition, rest MBF was positively correlated with worse diastolic function in women. We previously showed that mineralocorticoid blockade improved CFR in men and women with type 2 diabetes, implicating aldosterone in the pathophysiology of coronary microvascular dysfunction. We therefore examined aldosterone levels and found that women had larger increases in aldosterone in response to an angiotensin-II infusion than did men. In conclusion, among individuals with type 2 diabetes and good cardiometabolic control, women had worse myocardial perfusion and diastolic function compared with men. The greater aldosterone responsivity in women may be a mechanism for this sex effect.

Trial registration: ClinicalTrials.gov NCT00865124.

© 2018 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Sex differences in rest MBF, stress MBF, CFR, and diastolic function. A: Median rest MBF was 0.63 mL/g/min in men (IQR 0.57–0.73) and 0.86 mL/g/min in women (IQR 0.71–0.95). *P < 0.001. B: Median stress MBF was 1.83 mL/g/min in men (IQR 1.65–2.07) and 2.17 mL/g/min in women (IQR 1.83–2.33, P = 0.08). C: Median CFR was 2.85 in men (IQR 2.41–3.46) and 2.38 in women (IQR 1.92–3.09). *P = 0.008. D: Median diastolic function (E/e′) was 6.3 in men (IQR 5.4–7.5) and 7.3 in women (IQR 5.6–9.4). *P = 0.008. Higher E/e′ values indicate worse diastolic function. All P values were adjusted for HbA1c, BMI, race, SBP, statin use, and age.
Figure 2
Figure 2
A: Partial correlation of log-transformed rest MBF and log-transformed diastolic function (E/e′) among women (partial coefficient = 0.43 and P = 0.05). Higher E/e′ values correspond with worse diastolic function. B: There was no significant partial correlation of log-transformed rest MBF and log-transformed diastolic function (E/e′) among men (partial coefficient = 0.0054 and P = 0.97).
Figure 3
Figure 3
Sex differences in aldosterone response to angiotensin-II. Men had smaller increases in aldosterone in response to angiotensin-II infusion (median ∆4.77 ng/dL [IQR 2.72–7.35]) than women (median ∆7.85 ng/dL [IQR 5.76–10.28]). *P = 0.027.

References

    1. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998;351:1425–1427
    1. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995;155:57–61
    1. Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 2005;48:856–861
    1. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991;265:627–631
    1. Regensteiner JG, Golden S, Huebschmann AG, et al. .; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Epidemiology and Prevention, Council on Functional Genomics and Translational Biology, and Council on Hypertension . Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American heart association. Circulation 2015;132:2424–2447
    1. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol 2009;54:1561–1575
    1. Herzog BA, Husmann L, Valenta I, et al. . Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54:150–156
    1. Cortigiani L, Rigo F, Gherardi S, et al. . Prognostic effect of coronary flow reserve in women versus men with chest pain syndrome and normal dipyridamole stress echocardiography. Am J Cardiol 2010;106:1703–1708
    1. Murthy VL, Naya M, Taqueti VR, et al. . Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 2014;129:2518–2527
    1. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003;41:1387–1393
    1. Pepine CJ, Ferdinand KC, Shaw LJ, et al. .; ACC CVD in Women Committee . Emergence of nonobstructive coronary artery disease: a woman’s problem and need for change in definition on angiography. J Am Coll Cardiol 2015;66:1918–1933
    1. Murthy VL, Naya M, Foster CR, et al. . Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012;126:1858–1868
    1. Garg R, Rao AD, Baimas-George M, et al. . Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 2015;64:236–242
    1. Rao AD, Shah RV, Garg R, et al. . Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus. Am J Cardiol 2013;112:73–78
    1. American Diabetes Association Standards of medical care in diabetes--2012. Diabetes Care 2012;35(Suppl. 1):S11–S63
    1. Baudrand R, Pojoga LH, Vaidya A, et al. . Statin use and adrenal aldosterone production in hypertensive and diabetic subjects. Circulation 2015;132:1825–1833
    1. Taqueti VR, Shaw LJ, Cook NR, et al. . Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with severely impaired coronary flow reserve, not obstructive disease. Circulation 2017;135:566–577
    1. Gupta A, Taqueti VR, van de Hoef TP, et al. . Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation 2017;136:2325–2336
    1. Pries AR, Badimon L, Bugiardini R, et al. . Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. Eur Heart J 2015;36:3134–3146
    1. Ibarrola J, Sadaba R, Martinez-Martinez E, et al. . Aldosterone impairs mitochondrial function in human cardiac fibroblasts via A-kinase anchor protein 12. Sci Rep 2018;8:6801.
    1. Kaufmann PA, Camici PG. Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med 2005;46:75–88
    1. Bender SB, DeMarco VG, Padilla J, et al. . Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension 2015;65:1082–1088
    1. Brown SM, Meuth AI, Davis JW, Rector RS, Bender SB. Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: a unique vascular transcriptomic signature. Pharmacol Res 2018;134:100–108
    1. Rocha R, Stier CT Jr, Kifor I, et al. . Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871–3878
    1. Ibarrola J, Sadaba R, Martinez-Martinez E, et al. . Aldosterone impairs mitochondrial function in human cardiac fibroblasts via A-kinase anchor protein 12. Sci Rep 2018;8:6801.
    1. Shukri MZ, Tan JW, Manosroi W, et al. . Biological sex modulates the adrenal and blood pressure responses to angiotensin II. Hypertension 2018;71:1083–1090

Source: PubMed

Подписаться